Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Anixa Biosciences Inc (ANIX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Anixa Biosciences's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
3.090 +0.120    +4.04%
01/05 - Closed. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 58,633
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 2.980 - 3.150
Anixa Biosciences 3.090 +0.120 +4.04%

Anixa Biosciences Inc Company Profile

 
Get an in-depth profile of Anixa Biosciences Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

-

Equity Type

ORD

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company’s therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Contact Information

Address 3150 Almaden Expressway Suite 250
San Jose, 95118
United States
Phone 408 708 9808
Fax -

Top Executives

Name Age Since Title
Daniel Abate-Daga - 2018 Member of Scientific Advisory Board
H. Michael Shepard - - Member of Scientific Advisory Board
Linda L. Kelley 68 2018 Member of Scientific Advisory Board
Jose Conejo-Garcia - 2018 Member of Scientific Advisory Board
Marco L. Davila - 2018 Member of Scientific Advisory Board
Lewis H. Titterton 79 2012 Lead Independent Director
Ian Hector Frazer - 2019 Member of Scientific Advisory Board
Emily Gottschalk 62 2019 Independent Director
Hope S. Rugo - 2023 Member of Breast Cancer Clinical Advisory Board
Brian Czerniecki - 2023 Member of Breast Cancer Clinical Advisory Board
G. Thomas Budd - 2023 Member of Breast Cancer Clinical Advisory Board
Lisa H. Butterfield - 2023 Member of Breast Cancer Clinical Advisory Board
Brian Leyland-Jones 73 2023 Member of Breast Cancer Clinical Advisory Board
Karen E. Knudsen - 2023 Member of Cancer Business Advisory Board
Robert E. Youle - 2023 Member of Cancer Business Advisory Board
Daniel P. Heist - 2023 Member of Cancer Business Advisory Board
Len Lichtenfeld - 2023 Member of Cancer Business Advisory Board
Scarlott K. Mueller - 2023 Member of Cancer Business Advisory Board
Michael T. Marquardt - 2023 Member of Cancer Business Advisory Board
Gary M. Reedy - 2023 Member of Cancer Business Advisory Board
Arnold M. Baskies 74 2018 Member of SAB & Breast Cancer Clinical Advisory Board, Co-Chair of CBAB and Independent Director
Mark A. Goldberg 69 2023 Member of Cancer Business Advisory Board
Pamela D. Garzone 68 2021 Chief Development Officer & Chair Breast Cancer Clinical Advisory Board
Amit Kumar 60 2012 CEO, Chairman & Co-Chair of CBAB
Sanjay Juneja - 2024 Member of Cancer Business Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ANIX Comments

Write your thoughts about Anixa Biosciences Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email